Inhibition of FGFR3 Upregulates MHC-I and PD-L1 Via TLR3/NF-kB Pathway in Muscle-invasive Bladder Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Jun 7

PMID 37283287

Authors

Wenbo Wu

Lei Chen

GaoZhen Jia

Qilin Tang

Bangmin Han

Shujie Xia

Qi Jiang

Haitao Liu

Affiliations

Soon will be listed here.

Abstract

Background: Improving the potency of immune response is paramount among issues concerning immunotherapy of muscle-invasive bladder cancer (MIBC).

Methods: On the basis of immune subtypes, we investigated possible molecular mechanisms involved in tumor immune escape in MIBC. According to the 312 immune-related genes, three MIBC immune subtypes were clustered.

Results: Cluster 2 subtype is characterized by FGFR3 mutations and has a better clinical prognosis. However, the expression levels of MHC-I and immune checkpoints genes were the lowest, indicating that this subtype is subject to immune escape and has a low response rate to immunotherapy. Bioinformatics analysis and immunofluorescence staining of clinical samples revealed that the FGFR3 is involved in the immune escape in MIBC. Besides, after FGFR3 knockout with siRNA in RT112 and UMUC14 cells, the TLR3/NF-kB pathway was significantly activated and was accompanied by upregulation of MHC-I and PD-L1 gene expression. Furthermore, the use of TLR3 agonists poly(I:C) can further improve the effect.

Conclusion: Together, our results suggest that FGFR3 might involve in immunosuppression by inhibition of NF-kB pathway in BC. Considering that TLR3 agonists are currently approved for clinical treatment as immunoadjuvants, our study might provide more insights for improving the efficacy of immunotherapy in MIBC.

Citing Articles

Jozimine A, a Dimeric Naphthylisoquinoline (NIQ) Alkaloid, Shows In Vitro Cytotoxic Effects against Leukemia Cells through NF-κB Inhibition.

Damiescu R, Yucer R, Klauck S, Bringmann G, Efferth T, Dawood M Int J Mol Sci. 2024; 25(6).

PMID: 38542061 PMC: 10970593. DOI: 10.3390/ijms25063087.

Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.

Wu W, Chen L, Jia G, Tang Q, Han B, Xia S Cancer Med. 2023; 12(14):15676-15690.

PMID: 37283287 PMC: 10417096. DOI: 10.1002/cam4.6172.

References

Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A . Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia. 2010; 12(7):539-49. PMC: 2907580. DOI: 10.1593/neo.92106. View

Jongsma M, Guarda G, Spaapen R . The regulatory network behind MHC class I expression. Mol Immunol. 2017; 113:16-21. DOI: 10.1016/j.molimm.2017.12.005. View

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L . Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019; 25(12):1916-1927. PMC: 6898788. DOI: 10.1038/s41591-019-0654-5. View

Garrido M, Rodriguez T, Zinchenko S, Maleno I, Ruiz-Cabello F, Concha A . HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics. 2018; 70(10):647-659. DOI: 10.1007/s00251-018-1074-2. View

Gu S, Zhang W, Wang X, Jiang P, Traugh N, Li Z . Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021; 11(6):1524-1541. PMC: 8543117. DOI: 10.1158/2159-8290.CD-20-0812. View

Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E . Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019; 381(4):338-348. DOI: 10.1056/NEJMoa1817323. View

Meissner M, Reichert T, Kunkel M, Gooding W, Whiteside T, Ferrone S . Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005; 11(7):2552-60. DOI: 10.1158/1078-0432.CCR-04-2146. View

Mitchell S, Vargas J, Hoffmann A . Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016; 8(3):227-41. PMC: 8363188. DOI: 10.1002/wsbm.1331. View

Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S . PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nat Immunol. 2019; 20(9):1231-1243. PMC: 7472661. DOI: 10.1038/s41590-019-0441-y. View

10.

van Lingen A, Witjes J . Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2013; 13(10):1371-85. DOI: 10.1517/14712598.2013.824421. View

11.

Flippot R, Loriot Y . The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle?. Eur Urol. 2020; 78(5):688-689. DOI: 10.1016/j.eururo.2020.08.016. View

12.

Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z . Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Netw Open. 2020; 3(4):e202149. PMC: 7139278. DOI: 10.1001/jamanetworkopen.2020.2149. View

13.

Sun J, Fang G, Zuo Z, Yu X, Xue L, Li C . Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. Technol Cancer Res Treat. 2021; 20:15330338211045823. PMC: 8521413. DOI: 10.1177/15330338211045823. View

14.

Inoue J, Gohda J, Akiyama T, Semba K . NF-kappaB activation in development and progression of cancer. Cancer Sci. 2007; 98(3):268-74. PMC: 11158158. DOI: 10.1111/j.1349-7006.2007.00389.x. View

15.

Lin H, Wang K, Xiong Y, Zhou L, Yang Y, Chen S . Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Front Immunol. 2022; 13:773264. PMC: 8847306. DOI: 10.3389/fimmu.2022.773264. View

16.

Shi M, Meng X, Lamy P, Rouf Banday A, Yang J, Moreno-Vega A . APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol. 2019; 76(1):9-13. DOI: 10.1016/j.eururo.2019.03.032. View

17.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

18.

Li R, He Y, Zhang H, Wang J, Liu X, Liu H . Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Front Immunol. 2021; 12:690056. PMC: 8320597. DOI: 10.3389/fimmu.2021.690056. View

19.

Wang L, Gong Y, Saci A, Szabo P, Martini A, Necchi A . Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019; 76(5):599-603. PMC: 6801024. DOI: 10.1016/j.eururo.2019.06.025. View

20.

Wu W, Jia G, Chen L, Liu H, Xia S . Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer. Front Genet. 2021; 12:731625. PMC: 8414640. DOI: 10.3389/fgene.2021.731625. View